Form 8-K - Current report:
SEC Accession No. 0001069530-22-000063
Filing Date
2022-12-22
Accepted
2022-12-22 16:56:24
Documents
13
Period of Report
2022-12-19
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K sava-20221219x8k.htm   iXBRL 8-K 81962
2 EX-3.1 sava-20221219xex3_1.htm EX-3.1 10498
  Complete submission text file 0001069530-22-000063.txt   218144

Data Files

Seq Description Document Type Size
3 EX-101.SCH sava-20221219.xsd EX-101.SCH 2658
4 EX-101.LAB sava-20221219_lab.xml EX-101.LAB 15766
5 EX-101.PRE sava-20221219_pre.xml EX-101.PRE 11262
7 EXTRACTED XBRL INSTANCE DOCUMENT sava-20221219x8k_htm.xml XML 5063
Mailing Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731
Business Address 6801 N CAPITAL OF TEXAS HIGHWAY BUILDING 1; SUITE 300 AUSTIN TX 78731 512-501-2444
CASSAVA SCIENCES INC (Filer) CIK: 0001069530 (see all company filings)

EIN.: 911911336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 000-29959 | Film No.: 221482596
SIC: 2834 Pharmaceutical Preparations